Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose.
Stuyver
Lieven J
LJ
Pharmasset, Inc., Tucker, Ga., USA.
McBrayer
Tamara R
TR
Schürmann
Dirk
D
Kravec
Irena
I
Beard
Amanda
A
Cartee
Leanne
L
Schinazi
Raymond F
RF
De La Rosa
Abel
A
Murphy
Robert L
RL
Otto
Michael J
MJ
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D003570:Cytidine Triphosphate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors* / Q000235:genetics; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017423:Sequence Analysis, RNA; D019562:Viral Load; D016047:Zalcitabine / Q000031:analogs & derivatives
D018894:Reverse Transcriptase Inhibitors; D003570:Cytidine Triphosphate; D016047:Zalcitabine; D054303:HIV Reverse Transcriptase; C099405:dexelvucitabine